Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec;37(12):5411-5417.
doi: 10.1111/jocs.17231. Epub 2022 Nov 20.

Pearls, pitfalls, and surgical indications of the Intuity TM heart valve: A rapid deployment bioprosthesis. A systematic review of the literature

Aleksander Dokollari  1   2 , Gianluca Torregrossa  1   2 , Serge Sicouri  1 , Altin Veshti  3 , Rafik Margaryan  4 , Matteo Cameli  5 , Giulia Elena Mandoli  5 , Massimo Maccherini  5 , Gianfranco Montesi  5 , Francesco Cabrucci  6 , Lindita Coku  7 , Rakesh Arora  8 , Qiao Ri Li  9 , Massimo Bonacchi  6 , Sandro Gelsomino  10
Affiliations

Pearls, pitfalls, and surgical indications of the Intuity TM heart valve: A rapid deployment bioprosthesis. A systematic review of the literature

Aleksander Dokollari et al. J Card Surg. 2022 Dec.

Abstract

Objectives: To highlight short- and long-term clinical outcomes of the Intuity TM rapid deployment prosthesis for surgical aortic valve replacement.

Methods: We reviewed on PubMed/MEDLINE, Embase, SciELO, LILACS, CCTR/CENTRAL, and Google Scholar for clinical trials, retrospective clinical studies, meta-analysis, and gray literature.

Results: Fourty-five clinical studies with 12.714 patients were included in the analysis. Thirty-day mortality ranged from 3.8% for Intuity and 3.9% for transcatheter aortic valve replacement (TAVR). The incidence of paravalvular leak (PVL) (Intuity 0% and TAVR 2.17%), permanent pacemaker implantation (Intuity 11.11% and TAVR 12.5%), stroke (Intuity 2.2% and TAVR 2.6%), myocardial infarction (MI) (Intuity 0% and TAVR 1%), were all higher in the TAVR group. Compared to other sutured bioprosthesis (SB), mortality ranged from 0% to 3.9% for Intuity and 0%-6.9% for SB. Long-term cardiac mortality ranged from 0.9% to 1.55% for Intuity and 1.4%-3.3% for the Perceval valve. The incidence of PVL (Intuity 0.24%-0.7% and Perceval 0%-1%), endocarditis (Intuity 0.2%-0.7% and Perceval 1.6%-6.6%), stroke (Intuity 0.36%-1.4% and Perceval 0%-0.8%), MI (Intuity 0.07%-0.26%), and SVD (Intuity 0.12%-0.7% and Perceval 0%) were comparable. Compared to standard full sternotomy (SFS), minimally invasive surgery (MINV) mortality ranged from 0% to 4.3% for MINV and 0%-2.1% for SFS. Hospital costs outcomes ranged from $37,187-$44,368 for the Intuity, $69,389 for TAVR, and $13,543 for SB. Intuity short-term mortality ranged between 0.9% and 12.4% while long-term mortality ranged between 2.6% and 20%.

Conclusions: This manuscript provides a 360° overview of the current rapid deployments, sutureless, and TAVR prosthesis.

Keywords: Intuity; TAVR; aortic valve; echocardiography; long-term outcomes; perceval; rapid-deployment; sutured valves.

PubMed Disclaimer

References

REFERENCES

    1. Borger MA, Moustafine V, Conradi L, et al. A randomized multicenter trial of minimally invasive rapid deployment versus conventional full sternotomy aortic valve replacement. Ann Thorac Surg. 2015;99(1):17-25. doi:10.1016/j.athoracsur.2014.09.022
    1. Kocher AA, Laufer G, Haverich A, et al. One-year outcomes of the surgical treatment of aortic stenosis with a next generation surgical aortic valve (TRITON) trial: a prospective multicenter study of rapid-deployment aortic valve replacement with the EDWARDS INTUITY valve system. J Thorac Cardiovasc Surg. 2013;145(1):110-116. doi:10.1016/j.jtcvs.2012.07.108
    1. ClinicalTrials.gov Identifier. Surgical treatment of aortic stenosis with a next generation, rapid deployment surgical aortic valve deployment surgical aortic valve: NCT0 1700439.
    1. Lorusso R, Jiritano F, Roselli E, et al. Perioperative platelet reduction after sutureless or stented valve implantation: results from the PERSIST-AVR controlled randomized trial. Eur J Cardiothorac Surg. 2021;60(6):1359-1365. doi:10.1093/ejcts/ezab175
    1. Dokollari A, Ramlawi B, Torregrossa G, et al. Benefits and pitfalls of the perceval sutureless bioprosthesis. Front Cardiovasc Med. 2022;8:5. doi:10.3389/fcvm.2021.789392

Publication types

MeSH terms

LinkOut - more resources